去天津龙济个包皮天津市武清区龙济医院男科口碑如何,天津武清区龙济医院割包皮多少钱,天津武清龙济医院影院包皮手术怎样,武清龙济男性疾病治疗中心,武清区龙济必尿外科怎么样,天津武清龙济医院外科泌尿专家,包皮手术哪家医院好龙济男科

WASHINGTON, July 26 (Xinhua) -- The District of Columbia Department of Health (DOH) in the U.S. announced Tuesday that it has positively identified the West Nile Virus in mosquito samples in the District.This is the first time this summer the West Nile Virus has been identified in the U.S. capital."Residents should take caution as mosquitoes have the potential to transmit West Nile Virus to humans, and it is important for residents to take the necessary steps to avoid contracting the virus," DOH said in a statement.West Nile Virus is mainly an infection of birds, but on occasions an infected mosquito may spread it to humans. The virus is not transmitted directly from birds to humans and the risk of infection is low. In human infections, the virus generally causes no symptoms, or may cause mild flu-like symptoms.Senior citizens and people with weak immune systems are considered high risk for suffering the worst from the disease, officials said."People with a higher risk of infection should wear long- sleeved shirts, long pants, and apply insect repellent with DEET or other mosquito repellents to exposed skin according to manufacturer's directions. For children, they should use a product with DEET concentration of less than 30 percent," DOH said.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Aug. 1 (Xinhua) -- The provinces of Guizhou and Hunan reported their lowest levels of precipitation since 1951 in July, the China Meteorological Administration (CMA) said on Monday.Precipitation levels across the country saw a decrease of 8.7 percent from the average level of 115.9 mm in July, the lowest levels seen in 11 years, said Chen Zhenlin, an expert with the CMA.The average temperature recorded across the country in July was 22.1 degrees Celsius, up 0.7 degrees Celsius from the average level.

LOS ANGELES, Sept. 10 (Xinhua) -- Scientists at the University of California Los Angeles campus have announced that they have successfully used new prediction algorithms to forecast climate up to 16 months in advance.Professor Michael Ghil said in a UCLA news release Friday his team used new prediction algorithms based on matching ocean temperature records with new theories on how long-term climate trends are influenced by short-term weather extremes.That's twice as far into the future as previously accomplished.Ghil, a distinguished professor of climate dynamics in the UCLA Department of Atmospheric and Oceanic Sciences and senior author of the research, said the new prediction formulas will give climate experts and governments clues about long-term swings in the El Nino/La Nina oscillation in the Pacific Ocean, which drastically affects weather in the Americas, Asia and Australia.The new forecasting tool uses sea temperatures and has been tested on decades of historical data. The forecasts were then cross-checked against actual climate trends.The UCLA team also said that their 16-month forecasts were more accurate than previous forecasts that went only 8 months forward.Ghil emphasized that the forecasting tools are for climate, which is long-range, global patterns, but not for meteorology, which is short-term weather forecasting."Certain climate features might be predictable, although not in such detail as the temperature and whether it will rain in Los Angeles on such a day two years from now," said Ghil, who is also a member of UCLA's Institute of Geophysics and Planetary Physics. "These are averages over larger areas and longer time spans."The study is currently available online in the journal Proceedings of the National Academy of Sciences (PNAS) and will be published in an upcoming print edition of the journal.

WASHINGTON, Aug. 17 (Xinhua) -- Latest research shows that the Moon could be younger than previous estimates. The findings were published online Wednesday in the Nature journal.The prevailing theory of the Moon's origin is that it was created by a giant impact between a large planet-like object and the proto-Earth. The energy of this impact was sufficiently high that the Moon formed from melted material that was ejected into space. As the Moon cooled, this magma solidified into different mineral components. Analysis of lunar rock samples thought to have been derived from the original magma has given scientists a new estimate of the Moon's age.According to this theory for lunar formation, a rock type called ferroan anorthosite, or FAN, is the oldest of the Moon's crustal rocks, but scientists have had difficulty dating FAN samples. The research team used newly refined techniques to determine the age of a sample of FAN from the lunar rock that was brought back to Earth by the Apollo 16 mission in 1972.The team analyzed the isotopes of the elements lead and neodymium to place the FAN sample's age at 4.36 billion years. This figure is significantly younger than earlier estimates of the Moon's age that range as old as the age of the solar system at 4. 568 billion years. The new, younger age obtained for the oldest lunar crust is similar to ages obtained for the oldest terrestrial minerals -- zircons from western Australia -- suggesting that the oldest crusts on both Earth and Moon formed at approximately the same time, and that this time dates from shortly after the giant impact.This study is the first in which a single sample of FAN yielded consistent ages from multiple isotope dating techniques. This result strongly suggests that these ages pinpoint the time at which the sample crystallized."The extraordinarily young age of this lunar sample either means that the Moon solidified significantly later than previous estimates, or that we need to change our entire understanding of the Moon's geochemical history," Carnegie Institute of Science's geochemist and study author Richard Carlson said.